Osteoarthritis is a chronic disease characterized by progressive destruction of articular cartilage and subchondral bone, and synovial reaction. Clinical and radiologic findings that form the basis of the diagnosis of osteoarthritis are poorly sensitive for monitoring the progression of the disease. Biologic markers reflecting quantitative and dynamic changes of joint tissue turnover represent promising adjunct tools.
NTX-I
N-terminal cross-linked type I collagen OA osteoarthritis PIICP C-propeptide of type II procollagen PIINP N-propeptide of type II procollagen
ISSN 1040-8711 © 2003 Lippincott Williams & Wilkins
Osteoarthritis (OA) is a prevalent age-related disease that causes significant morbidity. The major clinical manifestation of OA is abnormal and degraded cartilage, inflamed and/or thickened synovial tissue, and altered bone structure, resulting in pain, mobility impairment, and disability. The severity of the disease is generally scored according to pain and mobility indices, but it remains difficult to quantify these parameters. Plain radiography, the reference technique for assessing the severity of joint destruction, provides direct information on bones but only indirect information on cartilage. Furthermore, sensitivity to change is limited, and it is often necessary to wait 1 to 3 years to obtain reliable information on progression. MRI provides direct information on the alteration of the different joint tissues and is currently being optimized in OA. Conventional laboratory tests such as ultrasensitive serum C-reactive protein show inflammation in some patients with OA but are not specific and provide little information on joint damage. Given the limitation of currently available investigations, there has been considerable interest in developing specific biologic markers that reflect quantitative and dynamic variations in joint tissue remodeling as exemplified by the recent National Institutes of Health initiative, a 7-year project in partnership with pharmaceutical companies to identify biologic markers for the progression of OA [1] . We briefly review the recent development in biologic markers and explore their potential clinical uses in OA.
Candidate biologic markers for osteoarthritis
The joint is a complex organ, and the OA process alters the metabolism of different tissues including bone, cartilage, and synovial membrane. To evaluate the mechanisms involved in joint destruction, the simultaneous use of markers for these three tissues could be useful. The extracellular matrix of these tissues is composed primarily of collagens, including type I (bone and synovium), type II (cartilage), and type III (synovium) associated with proteoglycans (eg, aggrecan in cartilage), and other glycoproteins [2] . Potential biologic markers for OA include matrix components (and/or their breakdown products), cytokines, and proteases (eg, matrix metalloprote-ases; Table 1 
Cartilage markers
The level of cartilage synthesis can be evaluated by assaying epitopes located on the chondroitin sulfate chains of the aggrecan (eg, 846 epitope), propeptides of type II collagen (C-propeptide of type II procollagen [PIICP] and N-propeptide of type II procollagen [PIINP]), or other proteins such as YKL-40 and cartilage-derived retinoic-acid sensitive protein. Cartilage-derived retinoic acid-sensitive protein, also referred to as melanomainhibiting activity, was originally isolated from malignant melanoma cells [8] . However, during physiologic conditions, cartilage-derived retinoic acid-sensitive protein seems to be expressed only by chondrocytes. Two studies reported decreased synovial fluid levels of cartilagederived retinoic acid-sensitive protein with increasing cartilage degradation in knee OA, suggesting that this marker could reflect the restorative reaction of chondrocytes [9, 10] . PIICP and PIINP are particularly interest- (Fig. 1) . Those directed against the neoepitopes generated by the collagenases (COL2-3/4 long mono and COL2-3/4C short) have been used mainly to demonstrate increased type II collagen cleavage in OA cartilage explants. A recent study showed a twofold increase in synovial fluid levels of COL2-3/4 long mono in a canine model of joint instability that develops OA [17] . Two different assays recognizing a sequence, which can be either "unnitrated" or "nitrated," of the triple helix of type II collagen have also been reported (Fig. 1) . Preliminary data suggest that increased serum or urine levels of these markers could be associated with progression of knee OA [18] . Most of clinical data reviewed next have, however, been generated using urinary CTX-II [6].
Markers of synovitis
Investigation of synovial tissue metabolism in OA has received little attention. However, there is increasing evidence indicating alterations in synovial tissue metabolism in a nonnegligible proportion of patients with OA
[19] as well as a correlation between the severity of synovitis and the progression of joint destruction [20] . Several markers have been proposed to assess synovitis, including serum hyaluronan, N-propeptide of type III procollagen, and other noncollagenous protein such as YKL-40. However, these markers are not specific to synovial tissue [2] . We have characterized a glycosylated pyridinoline derivative, glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD), which is found in large amounts in human synovium and in very low levels in the cartilage and other soft tissues [21] . Urinary Glc-Gal-PYD excretion is
Figure 1. Type II collagen fragments as specific biologic markers of cartilage degradation
Type II collagen is formed by the association of three identical ␣-1 chains in triple helix except at the ends (telopeptides). In the extracellular matrix of cartilage, collagen molecules are cross-linked by pyridinoline, involving the telopeptide regions. During cartilage degradation, different molecules are released in synovial fluid, serum, and urine. These include fragments of the triple helix carrying neo-epitopes generated by the collagenases (eg, COL2-3/4 long mono and COL2-3/4C short), fragments of the triple helix that can be "nitrated," and C-and N-terminal cross-linking telopeptides (eg, CTX-II 
Prediction of progression
Biologic markers will probably be more useful for predicting the progression of joint destruction. Indeed progression shows considerable variation across individuals, and the predictive capacity of clinical indices is poor. In a 4-year prospective study in postmenopausal women, urinary CTX-I and N-terminal cross-linked type I collagen were found to be higher in women with progressive knee OA compared with nonprogressive patients [28••] . Although the definition for progressive disease may not be the most adequate because it included a decrease of joint space width or osteophyte grade, these data suggest that increased bone resorption may be associated with progression. Increased baseline COMP levels were also shown to be associated with loss of joint space width over 3 years in a small population of patients with established knee OA [29] . The predictive value of synovial fluid level of PIICP was investigated in a select population of women who had knee pain during the past year but no radiologic evidence of joint space narrowing or subchondral bone sclerosis [30•]. Progression was evaluated by changes of joint space width at the tibiofemoral compartment over a 4-year period using semiflexed knee radiographs. Increased baseline PIICP levels were associated strongly with progression, suggesting that, early in the disease, acceleration of cartilage turnover (including synthesis) may indicate progressive cartilage loss [30•] . In a prospective study of 52 patients with established knee OA, we found that low serum levels of PIIANP or high urinary CTX-II excretion were associated with faster joint destruction evaluated over a 1-year period either by plain radiographs or by arthroscopy [12••] . Combining these two biologic markers to obtain an index of uncoupling of type II collagen synthesis and breakdown was more effective in predicting cartilage destruction than measurements of a single marker. Similarly, Cerejo et al. [31] showed that the baseline serum ratio of COL2-3/4 short to COL2-3/4C long mono, but not individual markers, was predictive of progression in patients with knee OA. Biologic marker data in hip OA are scarce. We showed that urinary CTX-II was significantly higher in patients with rapidly destructive hip OA than in patients with slowly progressive disease [32] . Similar findings were reported recently for serum matrix metalloprotease-3 and matrix metalloprotease-9 [33]. Finally, in two prospective studies of patients with early rheumatoid arthritis, we found that increased levels of CTX-I, CTX-II, and Glc-Gal-PYD at baseline were strongly predictive of radiologic progression over 1 to 5 years, independent of disease activity, serum C-reactive protein, and baseline radiologic damage [34,35••] .
Monitoring efficacy of structure modifying osteoarthritis treatment
One of the main issues that currently impairs efficient development of structure OA modifying therapies is the low sensitivity of plain radiographs, requiring long-term studies to show a significant difference between placebo and active drug-treated patients. Biologic markers may prove capable of providing earlier information compared with the demonstration of slowing of joint space narrowing by radiography. The paucity of data on the potential role of biologic markers for monitoring the treatment of OA is ascribed chiefly to the absence of medications with established chondroprotective activity. In patients with Paget disease of bone [36] and in postmenopausal women [37••] it has been shown that bisphosphonates, which are potent inhibitors of bone resorption, induce a rapid and dose-dependent decrease of urinary CTX-II. These data suggest that bisphosphonates may have chondroprotective effects, a possibility that is currently investigated in OA and rheumatoid arthritis. In a randomized placebo-controlled study in patients who had knee OA with clinical evidence of inflammation, the increases in Glc-Gal-PYD and CTX-II seen during 4 to 6 weeks of follow-up in the placebo group were blunted in the group given high doses of the nonsteroidal antiinflammatory drug ibuprofen [38] . A small placebocontrolled study has shown increased cartilage tissue levels of epitope 846 in patients with knee OA after treatment with an oral matrix metalloprotease inhibitor [39] , but larger studies with serum measurements are waiting to draw conclusions on the potential use of this marker. Rheumatoid arthritis may serve as a model to validate biologic markers because disease-modifying antirheumatic drugs that are effective in reducing radiographic progression are available. In the combinatietherapic big rheumatoide arthritis (COBRA) study, we recently found that the combined therapy sulfasalazine + methotrexate + prednisone, which is more efficient than sulfasalazine alone in reducing progression over 5 years, also produced a significantly higher decrease in urinary CTX-II, which can be observed within 3 months of therapy [40] . The magnitude of the changes of CTX-II at 3 months were predictive, independent of changes in disease activity, of the changes in radiologic scores after 5 years, indicating that the higher the decrease of CTX-II at 3 months, the lower the progression of joint damage at 5 years.
Conclusion
Recent work on biologic markers for OA has recently made valuable progress, in particular with the development of assays specific for the production and breakdown of type II collagen and of synovial membrane activity. Further research is needed to develop new assays based on fully characterized reagents, with the goal of improving sensitivity and specificity. An increasing body of evidence suggests that the combination of some biologic markers will be useful adjuncts to radiography and MRI for identifying patients at risk for rapid joint destruction. Finally, the rapid responsiveness of biologic markers should prove valuable in the clinical development of drugs for preventing joint destruction and in monitoring their treatment effects in patients with OA.
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